AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV Vaccines
"IL-12 Delivery from Recombinant Vaccinia Virus Attenuates the Vector and Enhances the Cellular Immune Response Against HIV-1 ENV in a Dose-Dependent Manner."
August 23rd, 1999
According to an abstract submitted by the authors to the Fourth European Conference on Experimental AIDS Research, held June 18-21, 1999 in Tampere, Finland, "To develop vaccination strategies against HIV-1 infection aimed to specifically enhance the cellular mediated immunity (CMI), we have engineered vaccinia virus (VV) recombinants expressing HIV-1 env (rVVenv), murine IL-12 (rVVlucIL12) genes, or co-expressing both genes (rVVenvIL-12). In mice inoculated with rVVenvIL-12 there is a rapid clearance of the virus, and this correlates with the induction of high levels of IL-12 and IFN-g in serum and in spleen early after infection. ELISPOT analysis from mice inoculated with rVVlucIL-12...
Source: AIDS Weekly (1999-08-23)
|
|
Advertisement |
|
|
